Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

DASGIP and Fraunhofer IZI cooperate in 1.1 Million Euro Stem Cell Project

11.04.2008
DASGIP AG, located in Juelich (Germany) and the Fraunhofer Institute for Cell Therapy and Immunology (IZI) in Leipzig (Germany) cooperate in stem cell research. The German Federal Ministry of Education and Research subsidizes a 1.1 Million € project aiming at the development of alternative drug testing methods without animal testing.

Taking prescription drugs during pregnancy can be harmful to the unborn child. Therefore, identifying the embryotoxic potential of a new drug candidate is an essential part of any preclinical study. These studies are currently conducted in animals according to OECD guidelines.

In Europe, 11 Million animals are tested annually. About 50 percent of these tests are performed to explore the bone harming and thus the embryotoxic potential of such drug candidates. Dr. Nicole zur Nieden, leader of the stem cell group at the Fraunhofer Institute, is developing a method to identify the bone harming potential in vitro.

This shall be enabled by simulating and monitoring the multi-phase differentiation process of pluripotent stem cells in a controlled bioreactor system. By adding compounds with known in vivo osteotoxic potential, adverse effects on the differentiation will be identified. Non human embryonic primate stem cells will be compared to human progenitor cells to study varying molecular reactions compared to the established test organisms (mice).

... more about:
»DASGIP »IZI »Stem »Testing »bioreactor »method

DASGIP, leading manufacturer of parallel bioreactor systems, will contribute its bioreactor system to the project. Through further improvements Dr. Matthias Arnold, CSO DASGIP, and the scientists at the Fraunhofer IZI plan to establish and automate a multi-step cultivation process covering the different phases of differentiating stem cells in drug testing.

The German government subsidizes the research project, acting on behalf of international organizations such as OECD and the EU. Since 1986 the EU commission has stressed its interest in new methods to minimize, replace or optimize animal testing. Recently, the demand to accelerate these processes has been increasing due to the EU Cosmetics and Chemicals Legislation and the desire to avoid complications associated with drug development. To date, only the embryonic stem cell test (EST) could prove as reliable ex vivo alternative to animal testing, which builds the basis for the planned improvements. The EU commission will publish its new ideas on how to reduce the need for animal testing and how to promote alternative methods sometime in April.

Not only politicians, but also industry representatives strongly appreciate the development of alternative methods as it can make drug development and approval faster and more cost-effective: In contrast to existing processes the stem cell approach promoted by Fraunhofer IZI is characterized by a high predictability for human effects, by cost-efficiency and by short testing periods. Therefore, Thomas Drescher, President of DASGIP, looks forward to providing the industry with a bioreactor system, which could help replacing up to 50 percent of the animal tests required in bone toxicity test for drugs, chemicals, plant protecting agents and cosmetics.

Further project partners are the ZEBET - Centre for Documentation and Evaluation of Alternatives to Animal Experiments - at the Federal Institute for Risk Assessment (http://www.bfr.bund.de/cd/1591) and the contract research organization RCC Ltd. (www.rccltd.ch).

| Fraunhofer Gesellschaft
Further information:
http://www.izi.fraunhofer.de
http://www.dasgip.com
http://www.bfr.bund.de/cd/1591

Further reports about: DASGIP IZI Stem Testing bioreactor method

More articles from Life Sciences:

nachricht Water forms 'spine of hydration' around DNA, group finds
26.05.2017 | Cornell University

nachricht How herpesviruses win the footrace against the immune system
26.05.2017 | Helmholtz-Zentrum für Infektionsforschung

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can the immune system be boosted against Staphylococcus aureus by delivery of messenger RNA?

Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent. The delivery of bacterial proteins with RNA adjuvant or messenger RNA (mRNA) into immune cells allows the re-direction of the immune response towards an active defense against S. aureus. This could be of significant importance for the development of an effective vaccine. PLOS Pathogens has published these research results online on 25 May 2017.

Staphylococcus aureus (S. aureus) is a bacterium that colonizes by far more than half of the skin and the mucosa of adults, usually without causing infections....

Im Focus: A quantum walk of photons

Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.

The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....

Im Focus: Turmoil in sluggish electrons’ existence

An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.

We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...

Im Focus: Wafer-thin Magnetic Materials Developed for Future Quantum Technologies

Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.

Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...

Im Focus: World's thinnest hologram paves path to new 3-D world

Nano-hologram paves way for integration of 3-D holography into everyday electronics

An Australian-Chinese research team has created the world's thinnest hologram, paving the way towards the integration of 3D holography into everyday...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Marine Conservation: IASS Contributes to UN Ocean Conference in New York on 5-9 June

24.05.2017 | Event News

AWK Aachen Machine Tool Colloquium 2017: Internet of Production for Agile Enterprises

23.05.2017 | Event News

Dortmund MST Conference presents Individualized Healthcare Solutions with micro and nanotechnology

22.05.2017 | Event News

 
Latest News

How herpesviruses win the footrace against the immune system

26.05.2017 | Life Sciences

Water forms 'spine of hydration' around DNA, group finds

26.05.2017 | Life Sciences

First Juno science results supported by University of Leicester's Jupiter 'forecast'

26.05.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>